title: [Coronary allograft vasculopathy: pathophysiological interaction between the immune system, infections and metabolic syndrome].
abstract: Cardiac allograft vasculopathy is still the main cause of long-term graft loss after heart transplantation. Indeed, recent advances in immunosuppression management led to a significant improvement in short-term survival, while long-term death rate did not change significantly in the last 20 years. In this paper, we will review the latest advances in the understanding of this peculiar form of atherosclerosis, focusing on the mechanisms that can be potentially targeted by specific therapeutic interventions.
authors.affiliation: Istituto di Malattie dell'Apparato Cardiovascolare, Università degli Studi, Bologna. luciano.potena2@unibo.it
authors.forename: Luciano
authors.initials: L
authors.lastname: Potena
authors.forename: Rossella
authors.initials: R
authors.lastname: Ferrara
authors.forename: Edward S
authors.initials: ES
authors.lastname: Mocarski
authors.forename: David B
authors.initials: DB
authors.lastname: Lewis
authors.forename: John P
authors.initials: JP
authors.lastname: Cooke
authors.forename: Francesco
authors.initials: F
authors.lastname: Grigioni
authors.forename: Fabio
authors.initials: F
authors.lastname: Coccolo
authors.forename: Gaia
authors.initials: G
authors.lastname: Magnani
authors.forename: Francesco
authors.initials: F
authors.lastname: Fallani
authors.forename: Carlo
authors.initials: C
authors.lastname: Magelli
authors.forename: Hannah A
authors.initials: HA
authors.lastname: Valantine
authors.forename: Angelo
authors.initials: A
authors.lastname: Branzi
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000378:metabolism; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology* / Q000276:immunology / Q000378:metabolism / Q000401:mortality / Q000517:prevention & control / Q000628:therapy; D003586:Cytomegalovirus Infections / Q000150:complications / Q000517:prevention & control; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000502:physiology; D006084:Graft Rejection; D006085:Graft Survival; D016027:Heart Transplantation / Q000009:adverse effects* / Q000401:mortality; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000150:complications; D011788:Quality of Life; D018570:Risk Assessment; D012307:Risk Factors; D012377:Rodentia; D015607:Stents; D013997:Time Factors
chemical_list: D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents; C018524:N,N-dimethylarginine; D001120:Arginine